PRCT logo

PROCEPT BioRobotics (PRCT) Company Overview

Profile

Full Name:

PROCEPT BioRobotics Corporation

Sector:

Healthcare

Country:

United States

IPO:

September 15, 2021

Indexes:

Not included

Description:

PROCEPT BioRobotics focuses on developing advanced robotic systems for minimally invasive surgeries, particularly in urology. Their innovative technology aims to improve patient outcomes and enhance surgical precision, making procedures safer and more efficient for both doctors and patients.

Events Calendar

Earnings

Next earnings date:

Feb 25, 2025

Recent quarterly earnings:

Oct 28, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 2, 24 Morgan Stanley
Overweight
Nov 14, 24 Jefferies
Hold
Oct 30, 24 Truist Securities
Buy
Oct 8, 24 Piper Sandler
Overweight
Sep 16, 24 TD Cowen
Buy
Sep 3, 24 Truist Securities
Buy
Aug 22, 24 B of A Securities
Buy
Aug 2, 24 Wells Fargo
Overweight
Aug 2, 24 Truist Securities
Buy
Jul 16, 24 Truist Securities
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for PROCEPT BioRobotics?
  • Does PROCEPT BioRobotics pay dividends?
  • What sector is PROCEPT BioRobotics in?
  • What industry is PROCEPT BioRobotics in?
  • What country is PROCEPT BioRobotics based in?
  • When did PROCEPT BioRobotics go public?
  • Is PROCEPT BioRobotics in the S&P 500?
  • Is PROCEPT BioRobotics in the NASDAQ 100?
  • Is PROCEPT BioRobotics in the Dow Jones?
  • When was PROCEPT BioRobotics's last earnings report?
  • When does PROCEPT BioRobotics report earnings?
  • Should I buy PROCEPT BioRobotics stock now?

What is the ticker symbol for PROCEPT BioRobotics?

The ticker symbol for PROCEPT BioRobotics is NASDAQ:PRCT

Does PROCEPT BioRobotics pay dividends?

No, PROCEPT BioRobotics does not pay dividends

What sector is PROCEPT BioRobotics in?

PROCEPT BioRobotics is in the Healthcare sector

What industry is PROCEPT BioRobotics in?

PROCEPT BioRobotics is in the Medical Devices industry

What country is PROCEPT BioRobotics based in?

PROCEPT BioRobotics is headquartered in United States

When did PROCEPT BioRobotics go public?

PROCEPT BioRobotics's initial public offering (IPO) was on September 15, 2021

Is PROCEPT BioRobotics in the S&P 500?

No, PROCEPT BioRobotics is not included in the S&P 500 index

Is PROCEPT BioRobotics in the NASDAQ 100?

No, PROCEPT BioRobotics is not included in the NASDAQ 100 index

Is PROCEPT BioRobotics in the Dow Jones?

No, PROCEPT BioRobotics is not included in the Dow Jones index

When was PROCEPT BioRobotics's last earnings report?

PROCEPT BioRobotics's most recent earnings report was on Oct 28, 2024

When does PROCEPT BioRobotics report earnings?

The next expected earnings date for PROCEPT BioRobotics is Feb 25, 2025

Should I buy PROCEPT BioRobotics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions